Testosterone Treatment Lawsuits Granted Six-Week Extension For AndroGel Bellwether Process

Print

Testosterone Treatment Lawsuits Allege Low Testosterone Treatment Drugs, Including AndroGel, Cause Cardiovascular Injuries And Cardiac Death.

Testosterone Treatment Lawsuits-Wright-and-Schulte-LLCThe federal judge presiding over testosterone treatment lawsuits has given AbbVie, the maker of AndroGel, an additional six weeks to complete its discovery in preparation for trials. In doing so, U.S. District Judge Matthew Kennelly denied AbbVie’s request to extend the bellwether schedule by up to four months. AbbVie is one of six testosterone manufacturers defending themselves against testosterone treatment lawsuits that allege their testosterone replacement therapy products cause heart attack, stroke, blood clots and cardiac death in men who are prescribed the drugs.

The federal testosterone lawsuits are consolidated in a multidistrict litigation (MDL) in the U.S. District Court, Northern District of Illinois. The majority of the testosterone complaints are filed against AbbVie and Abbott Laboratories over their blockbuster product, AndroGel. As a result, AbbVie’s attorneys say they need three to four more months to obtain documents, collect medical records, and coordinate depositions from plaintiffs’ doctors, among other things. The AndroGel lawsuit cases are in the discovery process and bellwether trials are scheduled to begin in April 2017. In a recently issued Case Management Order (CMO), Judge Kennelly said he was concerned about the impact an extension would have on the pending testosterone cases in the MDL as well as the coordination with testosterone cases pending in state courts. In an attempt to “reduce the discovery burden” on both sides, Judge Kennelly said the court excluded six cases from AbbVie’s initial bellwether pool, which represents nearly 20 percent of the pool, and will select up to eight cases, instead of the original 12 cases, for bellwether trials. Barring something “unforeseeable,” Judge Kennelly said the court “is making no other modifications to the scope of discovery.” Plaintiffs’ attorneys have previously accused AbbVie of trying to delay the case selection process. (In re: Testosterone Replacement Therapy Product Liability Litigation – MDL No. 2545)

“We commend Judge Kennelly’s decision not to grant any more delays so that the testosterone MDL can continue moving forward,” says Wright & Schulte LLC, a law firm representing men in testosterone complaints in this federal MDL.

Wright & Schulte LLC continues to offer legal evaluations to men, or their survivors, who believe they have experienced cardiac events due to testosterone therapy drugs. Contact one of the firms attorneys by calling 1-800-399-0795 or visit www.yourlegalhelp.com for more information on Low-T Drug side-effects and the ongoing testosterone lawsuit litigation

Testosterone replacement therapy drugs, such as Axiron, Fortesta, Delatestryl, are approved by the U.S. Food and Drug Administration (FDA) to treat low testosterone levels in men caused by a medical condition and not by the aging process.In January 2014, the FDA announced that it would conduct a review of all testosterone gels, creams and injections after reviewing studies that found increased cardiovascular risks associated with testosterone use in older men and younger men with pre-existing heart disease. In March 2015, the FDA ordered labels to be placed on prescription testosterone products warning of the potential increased risk of heart attack or stroke.
[fda.gov/Drugs/DrugSafety/ucm383904.htm, January 31, 2014]

Although AndroGel-related cases are scheduled for bellwether trial first, court records indicate that testosterone complaints against other drug makers are also moving forward with discovery. In addition to AbbVie and Abbott Laboratories, other testosterone manufacturers named as defendants in the MDL are:

  • Actavis, Inc. and Watson Pharmaceuticals, which makes AndroDerm
  • Auxilium Pharmaceuticals, Inc., which makes Testim
  • Eli Lilly and Company and Lilly USA LLC, makers of Axiron
  • Pharmaceuticals Inc., which makes Delatestryl and Fortesta
  • Pfizer Inc. and its subsidiary, Pharmacia & Upjohn Co. which makes and markets Depo-Testosterone

(In re: Testosterone Replacement Therapy ProductLiabilityLitigation – MDL No. 2545)

About Wright & Schulte LLC And Filing A Testosterone Treatment Lawsuit

Wright & Schulte LLC, an experienced personal injury firm, is dedicated to the belief that America’s legal system should work for the people. Every day, the attorneys of Wright Schulte LLC stand up for the rights of people who have been injured or wronged, and fight tirelessly to ensure that even the world’s most powerful corporations take responsibility for their actions. If you’re looking for a law firm that will guarantee the aggressive and personal representation you deserve, please do not hesitate to contact Wright & Schulte LLC today. Free testosterone lawsuit case evaluations are available through yourlegalhelp.com, or call 1-888-399-0795.

Contact:
Wright & Schulte LLC
865 S. Dixie Dr.
Vandalia, Ohio 45377
1-800-399-0795
http://www.yourlegalhelp.com

This entry was posted in Wright & Schulte Lawsuit News. Bookmark the permalink.